For in vivo pharmacokinetic study, six-week-old mice were intravenously injected with free DOX, NF@DOX and HEKM@DOX at the same DOX dosage of 10 mg/kg of mouse body weight (n =3 for each group), respectively. After injection, blood samples were harvested at predetermined time points (0.25, 0.5, 1, 2, 4, 8, 12, 24 and 48 h) . Then the plasma samples were collected immediately, repeatedly freeze-thawed and ultrasonicated for 3 min. After the plasma samples were subjected to centrifugation at 3000 rpm for 5min. Finally, the fluorescence of supernatant was examined by fluorescence spectroscopy (Ex, 480 nm; Em, 560-590 nm). Standard curves for DOX in blood were generated by the addition of free DOX at different concentrations to whole blood followed by extraction and quantification as mentioned above. Figure S15 . Western blot assay of the SKBR-3 cell and tumor tissue lysate towards the MMP-2 antibody. β-actin was used as a loading control.
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Figure S16. Pharmacokinetics profiles of DOX after intravenous injection of free DOX, NF@DOX and HEKM@DOX at 10 mg/kg dose in mice (mean ± SD, n = 3). Figure S17 . H&E staining analysis of heart, liver, spleen, lung, kidney of SKBR-3 tumor bearing xenograft mice after treatment with PBS, free DOX, HEKM DOX , NFM DOX and KLA (scale bar is 100 µm for all images).
